On September 16, 2022 Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, reported that an oral presentation of its Phase 1/2 clinical trial of EO2401 in patients with first progression/recurrence of glioblastoma (ROSALIE trial), will be made at the European Association of Neuro-Oncology (EANO) Meeting 2022 (Vienna, Austria) in the Award Winning Abstracts session on Saturday, September 17 at 16:00 CEST (full details below) by Professor Ahmed Idbaih, Sorbonne University, AP-HP La Pitié-Salpêtrière & Paris Brain Institute (Paris, France) and a clinical investigator in the ROSALIE trial (Press release, Enterome, SEP 16, 2022, View Source [SID1234619604]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

EO2401 is Enterome’s first-in-class off-the-shelf OncoMimics cancer immunotherapy. It combines three OncoMimics peptides that closely mimic IL13Ra2, BIRC5 and FOXM1, which are known driver antigens present on aggressive solid tumors. In addition, EO2401 contains a CD4 helper peptide UCP2. Enterome selected these OncoMimics peptides using its Mimicry platform, which applies best-in-class biocomputational tools and bioassays to identify novel therapeutics from its proprietary database of 20+ million bioactive gut microbiome peptides and proteins.

Professor Ahmed Idbaih said, "Immunotherapies have dramatically improved the prognosis of multiple cancers. At EANO we will be presenting our promising results with a new highly innovative immunotherapy, the OncoMimics-based therapeutic cancer vaccine EO2401 in combination with nivolumab and/or bevacizumab in patients with glioblastoma. We are delighted to have this opportunity to share our findings with the neuro-oncology community at this prestigious meeting."

Highlights from the EO2401/ ROSALIE Phase 1/2 trial:

Data published to date confirm that EO2401 in combination with nivolumab +/- bevacizumab is well tolerated with a safety profile consistent with the safety profiles of nivolumab and bevacizumab.
EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific effector memory CD8+ T cells, correlating with efficacy.
Addition of bevacizumab to EO2401 and nivolumab supported longer treatment durations, and an increase of objective response rate (ORR – 55% vs. 10%), disease control rate (DCR – 82% vs. 34%), and progression-free survival (PFS – 5.5 months vs 1.8 months), with 3 of the first 11 patients showing complete remission.
Details on Enterome’s oral presentation at EANO (ROSALIE study)

The abstract has been published in the Official Journal of the Society for Neuro-Oncology and can be viewed here.

About ROSALIE

ROSALIE (EOGBM1-18, NCT04116658) is a multicenter, open-label, Phase 1/2 trial investigating EO2401 in combination with nivolumab, and in combination with nivolumab/bevacizumab in patients with glioblastoma at first progression/recurrence after surgery and adjuvant radiotherapy/temozolomide. The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in approximately 80 patients at centers in the US and Europe.

On September 15, 2022 Athebio AG, an innovation leader in the discovery and design of designed ankyrin repeat proteins (DARPins), reported that it has entered into a collaboration agreement with 3T Biosciences ("3T"), an immunotherapy company focused on discovering and developing next-generation therapies with curative potential based on its immune-response guided target discovery approach (Press release, AtheBio, SEP 15, 2022, View Source [SID1234638729]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, Athebio will provide 3T with Athebody DARPins selected from its proprietary library against undisclosed peptide antigens presented on the cell surface by major histocompatibility complex (MHC) proteins. 3T may option the selected Athebody DARPins for further development.

"We are looking forward to working with the highly talented team at 3T Biosciences. We believe that Athebody DARPins have ideal properties to optimally recognize pMHC targets with very high specificity, which is crucial to be successful in this space," said Patrik Forrer, CEO and Chairman at Athebio, and one of the inventors of the DARPin technology.

"Combined with other key characteristics like their superior manufacturability and their ease of constructing multi-specific binders, Athebody DARPins will prove a great asset for various molecular formats, including the field of T-cell engagement. We are looking forward to exploring this huge potential together with 3T Biosciences."

On September 15, 2022 Integral Molecular, the industry leader in discovering antibodies against complex membrane protein targets, reported that it has licensed a panel of monoclonal antibodies (MAbs) to CARTEXELL, enabling CARTEXELL to develop CAR-T cell therapies using Integral Molecular’s Claudin 18.2 (CLDN18.2) MAbs (Press release, Integral Molecular, SEP 15, 2022, View Source [SID1234623334]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Integral Molecular will provide an exclusive worldwide license to CARTEXELL to use the panel of high-affinity, high-specificity, and fully humanized CLND18.2 MAbs for the development of CAR-T cell therapies against solid tumors including gastric, lung, pancreatic and esophageal cancers. CARTEXELL will be solely responsible for all research, development, and commercial activities.

The CLND18.2 MAbs were isolated using Integral Molecular’s MPS Antibody Discovery platform which is uniquely tailored to deliver high-specificity, high-affinity antibodies against the most structurally challenging membrane protein targets including GPCRs, ion channels, transporters, and tight junction proteins.

"Claudin 18.2 is an exciting target for oncology therapeutics since it’s highly expressed in cancers such as gastric and esophageal cancers that are difficult to treat", said Joseph Rucker, PhD, Vice President of R&D at Integral Molecular. "We look forward to the synergy of our high-specificity MAbs with CARTEXELL’s CAR-T cell therapy technology to bring new therapies to patients."

"CAR-T cell therapy has revolutionized treatment options for blood cancers, but has been ineffective for solid tumors", said Jehee Suh, CEO of CARTEXELL. "We are excited by the promise of these Claudin 18.2 antibodies for targeting our CAR-T 2.0 technology which uses engineered cells and vectors to overcome the tumor microenvironment and provide more effective therapies."

On September 15, 2022 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), reported that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference (Press release, MediciNova, SEP 15, 2022, View Source [SID1234619617]). The event is taking place virtually on September 28 – 29, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O’Brien, JD/MBA, Vice President and Executive Officer, will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting by contacting Joe Diaz of Lytham Partners by phone at (602) 889-9660, by email at [email protected] or by registering at View Source

On September 15, 2022, SELLAS Life Sciences Group, Inc. (the "Company") presented the corporate presentation (Filing, 8-K, Sellas Life Sciences, SEP 15, 2022, View Source [SID1234619614]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!